Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials

BACKGROUND: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we review the design assumptions for pivotal ALS clinical trials with time-to-even...

Descripción completa

Detalles Bibliográficos
Autores principales: van Eijk, Ruben P A, Nikolakopoulos, Stavros, Roes, Kit C B, Middelkoop, Bas M, Ferguson, Toby A, Shaw, Pamela J, Leigh, P Nigel, Al-Chalabi, Ammar, Eijkemans, Marinus J C, van den Berg, Leonard H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Neuromuscular
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902062/
https://www.ncbi.nlm.nih.gov/pubmed/31292200
http://dx.doi.org/10.1136/jnnp-2019-320998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902062/
https://www.ncbi.nlm.nih.gov/pubmed/31292200
http://dx.doi.org/10.1136/jnnp-2019-320998

Ejemplares similares